{"id":69534,"date":"2026-07-07T21:02:10","date_gmt":"2026-07-07T13:02:10","guid":{"rendered":"https:\/\/flcube.com\/?p=69534"},"modified":"2026-07-07T21:02:12","modified_gmt":"2026-07-07T13:02:12","slug":"vertex-pharmaceuticals-to-acquire-crinetics-for-10b-adding-palsonify-and-atumelnant-to-endocrine-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69534","title":{"rendered":"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Vertex Pharmaceuticals Incorporated<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/VRTX:NASDAQ\">NASDAQ: VRTX<\/a>) and <strong>Crinetics Pharmaceuticals, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/CRNX:NASDAQ\">NASDAQ: CRNX<\/a>) announced a <strong>definitive acquisition agreement<\/strong> under which Vertex will acquire Crinetics for <strong>USD 85.00 per share in cash<\/strong>, representing a total <strong>equity value of approximately USD 10.0 billion<\/strong> (USD 8.8 billion net of estimated cash acquired).<\/p>\n\n\n\n<h2 id=\"h-transaction-details-amp-strategic-rationale\" class=\"wp-block-heading\">Transaction Details &amp; Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Vertex Pharmaceuticals (NASDAQ: VRTX)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Crinetics Pharmaceuticals (NASDAQ: CRNX)<\/td><\/tr><tr><td><strong>Purchase Price<\/strong><\/td><td>USD 85.00 per share in cash<\/td><\/tr><tr><td><strong>Total Equity Value<\/strong><\/td><td>Approximately USD 10.0 billion<\/td><\/tr><tr><td><strong>Net Consideration<\/strong><\/td><td>Approximately USD 8.8 billion (net of estimated cash acquired)<\/td><\/tr><tr><td><strong>Board Approval<\/strong><\/td><td>Unanimously approved by both companies&#8217; Boards of Directors<\/td><\/tr><tr><td><strong>Expected Closing<\/strong><\/td><td>Third quarter of 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-portfolio-amp-clinical-pipeline\" class=\"wp-block-heading\">Asset Portfolio &amp; Clinical Pipeline<\/h2>\n\n\n\n<h3 id=\"h-palsonify-paltusotine-commercial-asset\" class=\"wp-block-heading\">PALSONIFY (paltusotine) \u2013 Commercial Asset<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> First and only <strong>once-daily oral therapy<\/strong> for adults with <strong>acromegaly<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong><\/li>\n\n\n\n<li><strong>FDA approval:<\/strong> September 2025 (United States)<\/li>\n\n\n\n<li><strong>EMA approval:<\/strong> Recently granted (European Union)<\/li>\n\n\n\n<li><strong>Global status:<\/strong> Under review by other international regulatory bodies<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Addresses significant unmet need in acromegaly treatment, traditionally managed with injectable somatostatin analogs requiring frequent administration<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-atumelnant-phase-3-pipeline-candidate\" class=\"wp-block-heading\">Atumelnant \u2013 Phase 3 Pipeline Candidate<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> <strong>Congenital adrenal hyperplasia (CAH)<\/strong> \u2013 rare genetic disorder affecting cortisol production<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> <strong>Phase 3 clinical trials ongoing<\/strong><\/li>\n\n\n\n<li><strong>Phase 2 Results:<\/strong> Patients achieved <strong>near normalization of excess androgen levels<\/strong> while on physiologic replacement doses of glucocorticoids<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Generally well tolerated with <strong>no treatment-related severe or serious adverse events<\/strong> reported to date<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-synergies-amp-portfolio-enhancement\" class=\"wp-block-heading\">Strategic Synergies &amp; Portfolio Enhancement<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Strategic Benefit<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Endocrine Disease Expansion<\/strong><\/td><td>Complements Vertex&#8217;s existing rare disease expertise with established commercial asset and late-stage pipeline<\/td><\/tr><tr><td><strong>Oral Therapy Leadership<\/strong><\/td><td>Reinforces Vertex&#8217;s commitment to developing convenient, once-daily oral treatments for complex endocrine disorders<\/td><\/tr><tr><td><strong>Commercial Infrastructure Leverage<\/strong><\/td><td>Enables accelerated global rollout of PALSONIFY leveraging Vertex&#8217;s established international commercial organization<\/td><\/tr><tr><td><strong>R&amp;D Pipeline Diversification<\/strong><\/td><td>Adds validated ACTH receptor antagonist platform with potential applications beyond CAH<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Vertex Pharmaceuticals, known for its transformative cystic fibrosis therapies and expanding rare disease portfolio, continues its strategic evolution into endocrine and metabolic disorders with this acquisition.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Acromegaly Market:<\/strong> Estimated at $1.2 billion globally, dominated by injectable somatostatin analogs (Sandostatin, Somatuline) requiring monthly or daily injections<\/li>\n\n\n\n<li><strong>CAH Treatment Gap:<\/strong> Current standard of care involves high-dose glucocorticoid replacement with significant side effects; no targeted therapies approved<\/li>\n\n\n\n<li><strong>Oral Therapy Advantage:<\/strong> Once-daily oral administration represents major improvement in patient convenience and compliance compared to current injectable standards<\/li>\n\n\n\n<li><strong>Rare Disease Premium:<\/strong> Both indications qualify for orphan drug designation, supporting premium pricing and market exclusivity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-implications-amp-integration-strategy\" class=\"wp-block-heading\">Financial Implications &amp; Integration Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cash Transaction:<\/strong> Fully financed through Vertex&#8217;s strong balance sheet with approximately $9.5 billion in cash and marketable securities as of Q1 2026<\/li>\n\n\n\n<li><strong>Revenue Synergies:<\/strong> Immediate revenue contribution from PALSONIFY US launch combined with global expansion opportunities<\/li>\n\n\n\n<li><strong>Cost Synergies:<\/strong> Integration of Crinetics&#8217; ~200 employees into Vertex&#8217;s existing infrastructure with minimal overlap<\/li>\n\n\n\n<li><strong>Pipeline Acceleration:<\/strong> Enhanced resources expected to accelerate atumelnant Phase 3 completion and regulatory submissions<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the Vertex-Crinetics acquisition, including transaction closing, regulatory approvals, clinical development timelines, and commercial prospects. Actual results may differ due to risks including regulatory approvals, integration challenges, competitive developments, and market dynamics in the endocrine therapeutic landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4842,4843,1073,24,1074],"class_list":["post-69534","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-crinetics-pharmaceuticals","tag-nasdaq-crnx","tag-nasdaq-vrtx","tag-rare-orphan-disease-drugs","tag-vertex-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition agreement under which Vertex will acquire Crinetics for USD 85.00 per share in cash, representing a total equity value of approximately USD 10.0 billion (USD 8.8 billion net of estimated cash acquired).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69534\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio\" \/>\n<meta property=\"og:description\" content=\"Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition agreement under which Vertex will acquire Crinetics for USD 85.00 per share in cash, representing a total equity value of approximately USD 10.0 billion (USD 8.8 billion net of estimated cash acquired).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69534\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T13:02:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T13:02:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69534#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69534\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio\",\"datePublished\":\"2026-07-07T13:02:10+00:00\",\"dateModified\":\"2026-07-07T13:02:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69534\"},\"wordCount\":528,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Crinetics Pharmaceuticals\",\"NASDAQ: CRNX\",\"NASDAQ: VRTX\",\"Rare \\\/ orphan disease drugs\",\"Vertex Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69534#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69534\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69534\",\"name\":\"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-07T13:02:10+00:00\",\"dateModified\":\"2026-07-07T13:02:12+00:00\",\"description\":\"Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition agreement under which Vertex will acquire Crinetics for USD 85.00 per share in cash, representing a total equity value of approximately USD 10.0 billion (USD 8.8 billion net of estimated cash acquired).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69534#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69534\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69534#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition agreement under which Vertex will acquire Crinetics for USD 85.00 per share in cash, representing a total equity value of approximately USD 10.0 billion (USD 8.8 billion net of estimated cash acquired).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69534","og_locale":"en_US","og_type":"article","og_title":"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio","og_description":"Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition agreement under which Vertex will acquire Crinetics for USD 85.00 per share in cash, representing a total equity value of approximately USD 10.0 billion (USD 8.8 billion net of estimated cash acquired).","og_url":"https:\/\/flcube.com\/?p=69534","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-07T13:02:10+00:00","article_modified_time":"2026-07-07T13:02:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69534#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69534"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio","datePublished":"2026-07-07T13:02:10+00:00","dateModified":"2026-07-07T13:02:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69534"},"wordCount":528,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Crinetics Pharmaceuticals","NASDAQ: CRNX","NASDAQ: VRTX","Rare \/ orphan disease drugs","Vertex Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69534#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69534","url":"https:\/\/flcube.com\/?p=69534","name":"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-07T13:02:10+00:00","dateModified":"2026-07-07T13:02:12+00:00","description":"Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition agreement under which Vertex will acquire Crinetics for USD 85.00 per share in cash, representing a total equity value of approximately USD 10.0 billion (USD 8.8 billion net of estimated cash acquired).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69534#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69534"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69534#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69534"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69534\/revisions"}],"predecessor-version":[{"id":69535,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69534\/revisions\/69535"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}